Gastrointestinal Adverse Events with GLP-1 Receptor Agonists in Non-Diabetic Weight Management
Published: 13 August 2025
Rising Use of GLP-1 Receptor Agonists in Non-Diabetic Weight Management
Overweight and obesity remain critical global health challenges. These conditions increase the risk of cardiovascular disease, metabolic disorders, and certain cancers. Traditional interventions such as lifestyle modification and dietary changes often fail to deliver sustainable results. Therefore, pharmacotherapy, particularly GLP-1 receptor agonists (GLP-1 RAs), has emerged as a powerful adjunct in weight management for non-diabetic patients with overweight or obesity.
GLP-1 receptor agonists work by stimulating the GLP-1 receptor. This enhances insulin secretion, suppresses glucagon release, delays gastric emptying, and promotes satiety. As a result, they contribute to significant weight loss outcomes. However, these benefits are tempered by gastrointestinal adverse events that may limit adherence.
Why Gastrointestinal Adverse Events Demand Clinical Attention
Gastrointestinal adverse events are among the most common side effects of GLP-1 receptor agonists. These include nausea, vomiting, diarrhea, constipation, abdominal discomfort, and bloating. For non-diabetic patients undergoing weight management, tolerability is crucial. Even mild but persistent gastrointestinal symptoms can lead to discontinuation and suboptimal outcomes.
Systematic Review and Network Meta-Analysis Overview
A recent systematic review and dose-response network meta-analysis compiled data from 39 clinical trials, encompassing over 33,000 non-diabetic participants with overweight or obesity. The goal was to quantify the risk of gastrointestinal adverse events associated with GLP-1 receptor agonists and related agents, including tirzepatide and cagrilintide.
This comprehensive analysis compared drugs directly and indirectly, ranked their adverse event profiles and examined dose-response relationships.
Key Findings: Most Common Gastrointestinal Adverse Events
- Nausea – The Most Frequent Adverse Event
All GLP-1 receptor agonists significantly increased the nausea risk. Orforglipron presented the highest risk, followed by exenatide, tirzepatide, semaglutide, and liraglutide 4. Nausea risk rose rapidly at low doses and plateaued at higher doses.
- Vomiting – A Dose-Linked Concern
Vomiting risk was elevated with liraglutide, orforglipron, semaglutide, and tirzepatide. Cagrilintide and exenatide did not show a significant increase. The risk pattern often mirrored that of nausea but with higher relative risk values.
- Diarrhea – Variation Across Agents
Semaglutide, liraglutide, and tirzepatide were associated with higher diarrhea risk. In contrast, exenatide, cagrilintide, and orforglipron were not linked to a significant increase.
- Constipation – Prominent with Certain Agents
Constipation was significantly more likely with semaglutide, liraglutide, and tirzepatide. Other agents, including cagrilintide and exenatide, showed no significant association.
- Less Common but Clinically Relevant Events
- GERD: Only semaglutide showed a significant association.
- Eructation: Increased risk with liraglutide and semaglutide.
- Flatulence: More common with semaglutide and tirzepatide.
- Abdominal Pain: Notable with semaglutide, liraglutide, and tirzepatide.
Gallbladder disease, acute pancreatitis, and viral gastroenteritis risks were not significantly increased in this non-diabetic population.
Dose-Response Insights: Early Dose Escalation Risks
The dose-response analysis revealed a consistent pattern:
- Adverse events increased sharply at lower doses.
- Risk often plateaued at higher doses.
- This trend applied to nausea, vomiting, diarrhea, constipation, and decreased appetite.
These findings underscore the importance of gradual titration to enhance tolerability in weight management programs.
Clinical Implications for Non-Diabetic Weight Management
Balancing Efficacy and Tolerability
When prescribing GLP-1 receptor agonists for non-diabetic patients with overweight or obesity, healthcare professionals must weigh the significant weight loss benefits against the gastrointestinal adverse event profile.
Tailoring Agent Selection
- For patients highly sensitive to gastrointestinal discomfort, agents like cagrilintide or dulaglutide may be preferable.
- For those aiming for maximum weight loss, semaglutide or tirzepatide may be chosen with careful monitoring.
Mitigation Strategies
- Employ gradual dose escalation.
- Educate patients about expected gastrointestinal effects.
- Monitor closely during initiation and escalation phases.
Limitations and Future Directions
While this meta-analysis offers robust insights, heterogeneity in study design, dosing regimens, and follow-up duration limits generalizability. Additionally, most included studies were from specific geographic regions, and age-stratified gastrointestinal adverse event data were lacking.
Future research should focus on:
- Age and sex-specific tolerability profiles.
- Strategies to prevent gastrointestinal intolerance.
- Long-term adherence outcomes in non-diabetic weight management.
Conclusion: Optimizing Patient-Centered GLP-1 RA Therapy
GLP-1 receptor agonists are highly effective for weight management in non-diabetic patients with overweight or obesity. However, gastrointestinal adverse events are common and can impact adherence. By individualizing therapy, employing careful titration, and fostering shared decision-making, clinicians can optimize both efficacy and tolerability.
For healthcare professionals in Muslim weight management, understanding these safety profiles ensures informed prescribing that aligns with patient needs, cultural considerations, and long-term health outcomes.
SOURCE/READ FULL PAPER: https://www.nature.com/articles/s41366-025-01859-6
LEARN MORE ABOUT THE MUSLIM WEIGHT MANAGEMENT
